First treatment for lung cancer with EGFR exon 20 mutations
Part of Cancer, Lungs & breathing clinical trials.
This trial tests YK-029A as the first anti-cancer treatment instead of standard platinum chemotherapy for certain advanced non-small cell lung cancers with an EGFR exon 20 insertion mutation. It may help shrink or control tumors while improving how patients tolerate treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and have advanced or metastatic non-small cell lung cancer that can’t be treated with a sure cure (like surgery or main radiation).
- Your tumor test shows an EGFR exon 20 insertion mutation (in-frame), confirmed by a certified lab.
- Your EGFR mutation pattern can include other EGFR or HER2 changes, but you must NOT have specific known “standard” EGFR mutations that already have approved EGFR pill medicines (like exon 19 deletion or L858R).
- There’s at least one measurable tumor spot on scans, and doctors can use enough tumor tissue for their central confirmation test.
- You can likely tolerate treatment: your health status is good (ECOG 0–1) and your blood and organs are working well enough for chemotherapy-type treatment.
- You haven’t started prior anti-cancer medicine for advanced/metastatic disease (with limited exceptions), and you’re not having certain urgent conditions like spinal cord or brain covering fluid involvement.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called PH009-1 for people with advanced non-small cell lung cancer that has a specific change (EGFR mutation). It aims to see if the drug can shrink tumors and how safe it is.
This trial tests a new targeted drug (TY-9591) combined with chemotherapy as a first treatment for people with advanced non-small cell lung cancer that has a specific EGFR mutation. It may offer a more effective option for those who haven't had prior therapy.
This trial tests a new drug, YL202, against a standard chemotherapy (docetaxel) for people with a specific type of advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if YL202 works better for those whose cancer has progressed after prior treatments.
This study tests a new pill called PLB1004 for people whose lung cancer has a specific EGFR mutation (exon 20 insertion). It is for those who have not yet had any treatment for their advanced cancer.
This trial studies an oral (by mouth) EGFR-blocking medicine (DZD9008) in people with advanced lung cancer that has EGFR mutations. It’s for cancers that have grown despite standard treatment or couldn’t be tolerated, and aims to control the cancer while keeping side effects manageable.
This trial tests a new drug, HSK40118, for people with advanced non-small cell lung cancer (NSCLC) that has an EGFR mutation and has been treated with certain EGFR-targeted therapies before. The goal is to see if this drug can help when other treatments stop working.
Hear when a new Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.